RecruitingPhase 2NCT03844061

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hospital for Special Surgery, New York
Principal Investigator
Robert Spiera, MD
Hospital for Special Surgery, New York
Intervention
Belimumab(drug)
Enrollment
30 enrolled
Eligibility
18-80 years · All sexes
Timeline
20192026

Study locations (1)

Collaborators

GlaxoSmithKline

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03844061 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis

← Back to all trials